TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03850691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin: All Patients
Description: Cycle 1:~(600,000 U/kg/dose) given as a bolus infusion once every 8 to 12 hours over 5 days or until no longer tolerated (to a maximum of 10 doses). Administered as an inpatient.~Days 1-5 and Days 15-19 (all patients)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin: All Patients
Description: Cycle 1:~(600,000 U/kg/dose) given as a bolus infusion once every 8 to 12 hours over 5 days or until no longer tolerated (to a maximum of 10 doses). Administered as an inpatient.~Days 1-5 and Days 15-19 (all patients)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab: Cohort 1 (Cutaneous)
Description: Cycle 1: 6 Week Duration Nivolumab 240 mg IV~Cycle 2: 6 Week Duration Nivolumab 240 mg IV on Day 1, 15 and 29~Cycle 3: 4 Week Duration Nivolumab 240 mg IV on Day 1 and 15~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab: Cohort 2 (Ocular)
Description: Cycle 1: 6 Week Duration Nivolumab 3 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Nivolumab 1 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Nivolumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Nivolumab on Day 8 using the same dose regimen as used Cycle 1 Day 29.~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab: Cohort 2 (Ocular)
Description: Cycle 1: 6 Week Duration Ipilimumab 1 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Ipilimumab 3 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Ipilimumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Ipilimumab on Day 8 using the same dose regimen as used Cycle 1 Day 29
Study: NCT04618809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic Session
Description: This session will include an overview of the approach to and management of older mGC patients patients through a case-based presentation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment, including an exploratory analysis to evaluate the use of fitness trackers for evaluation of functional status.
Description: * The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.~* The patient will receive a FitBit TM to wear for 4 days. Number of steps/day will be recorded.
Study: NCT01281943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2
Description: Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle~Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle
Study: NCT01065298

Intervention type: BIOLOGICAL
Intervention: stem cell transplantation
Description: Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of \>40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
Study: NCT03706716

Intervention type: OTHER
Group type: OTHER
Intervention: decision aid developed for pelvic organ prolapse
Description: Conversation based upon the inter face in the Electronic patient journal.
Study: NCT04442698

Intervention type: PROCEDURE
Intervention: Mini-Gastric Bypass Original Technique
Description: Follow up of the Surgical procedure outcomes in diabetics. Procedure Mini-Gastric Bypass Original Technique
Study: NCT04260568

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Patients with a diagnosis of 3PD will be sought from a multidisciplinary balance clinic. Consenting participants will take part in a face-to-face interview about their diagnosis. Data collection will consist of recorded semi-structured interviews, which will be transcribed.
Study: NCT03873311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine, HAG Regimen
Description: Azacytidine（75mg/m2 QD for 7 days）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) for 14 days), Cytarabine 10mg/(m2.d) for 14 days, granulocyte colony-stimulating factor(G-CSF) 200ug/(m2.d) for 14 days until absolute neutrophil count(ANC) ≥ 10X109／L)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacytidine
Description: Azacytidine 75mg/m2 QD for 7 days.
Study: NCT02974803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 150 mg twice a day until progression or unaccepted toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg once daily until progression or unaccepted toxicity.
Study: NCT01964716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
Study: NCT03149822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Pharmaceutical form: tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Pharmaceutical form: tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Pharmaceutical form: tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: solution Route of administration: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: solution Route of administration: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: solution Route of administration: injection
Study: NCT01133496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate Sodium Tablets, 70 mg
Description: Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate Sodium Tablets, 70 mg
Description: Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
Study: NCT04337476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention
Description: Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention
Description: Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention
Description: Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.
Study: NCT06265571

Intervention type: OTHER
Intervention: perineural injection
Description: perineural injection of local anesthestetic for postoperative pain management

Intervention type: OTHER
Intervention: perineural injection
Description: perineural injection of local anesthestetic for postoperative pain management
Study: NCT04213833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol Injection [Diprivan]
Description: patients will be sedated with 50 mg propofol(10 mg/ml) given slowly intravenously over 1 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine [Precedex]
Description: patients will received 0.5 mcg/ kg dexmedetomidine intravenously followed by syringe containing 50 mg propofol(10 mg/ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palatable Lidocaine Topical Gel
Description: 15 g of palatable lidocaine gel will be gradually applied 3-5 min before the endoscopy at three consecutive 30-s intervals to the base of the tongue, the palate and the peritonsillar areas and the patients will be informed to spread it within their mouth with their tongue and swallow it later to cover the oropharynx and esophagus. Patients will be asked to register the onset of numbness, then patient will receive syringe containing 50 mg propofol (10 mg/ml) intravenously as a sedation.
Study: NCT01782768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive positive pressure ventilation
Description: the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
Study: NCT00947323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin 20 daily for six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04003194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinto Beans
Description: The intervention was 1/2 cup of pinto beans each day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Green Beans - control
Description: The control was 1/2 cup of green beans each day.
Study: NCT01473992

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Otto Bock C-Leg
Description: Amputees' preferred prosthetic knee.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Otto Bock Genium
Description: Study knee.
Study: NCT01758744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil Therapy
Description: Treprostinil: Inhaled prostanoid therapy
Study: NCT01159522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB01A
Description: This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
Study: NCT04730674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracycline mixed with xylocaine
Description: 10 cc of saline containing 2 gm of tetracycline mixed with 5 ml of 2% xylocaine (as a pain relieving agent) was injected at the seroma bed.
Study: NCT03174782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
Study: NCT03515447

Intervention type: OTHER
Intervention: Non interventional study
Study: NCT00859976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BoneMaster coated acetabular shell.
Description: Bonemaster coated Exceed Acetabular Shell

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Coated Acetabular Shell
Description: Plasma HA coated Exceed Acetabular Shell
Study: NCT03025932

Intervention type: PROCEDURE
Intervention: repair of giant hiatal hernia with mesh and anterior fundoplication
Study: NCT01257399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol®
Description: 400 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: 400mg tablets
Study: NCT02912754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
Study: NCT00298675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSI-201 (iniparib)
Description: BSI-201 administered intravenously (IV), 2x weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSI-201 (iniparib)
Description: BSI-201 administered intravenously (IV), 2x weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan administered weekly, IV.
Study: NCT04502797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Patient Visit Assessment (ePVA)
Description: The ePVA is an mHealth clinical support tool. The ePVA consists of a patient-reported measure that focuses on symptoms common to HNC (i.e. pain, eye, ear, nasal, mouth, voice, fibrosis, edema, skin, gastrointestinal, fatigue, limitation in movement, sleep, breathing, difficulty eating or drinking, swallowing, communication, social activities, anxiety, depression, and daily activities). PROMIS® questionnaires (pain intensity 3a, fatigue 6a, sleep disturbance 6a, anxiety 6a, depression 6a) are embedded within the ePVA.
Study: NCT02150395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Study: NCT02442193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Description: Individual Placement and Support is a form of supported employment.
Study: NCT04086238

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Capsules containing a combination of decitabine and THU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Capsules containing a combination of decitabine and THU
Study: NCT01464619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Incredible Years Parenting Intervention
Description: The Incredible Years Parents, Babies, and Toddlers Program is a validated group parenting education program, which has been adapted for use with depressed caregivers by inclusion of psychoeducational depression materials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed Intervention
Description: Caregivers assigned to delayed intervention will be assigned to the Incredible Years parenting intervention 3-4 months after enrollment.
Study: NCT03153683

Intervention type: OTHER
Intervention: Registry
Description: Collect standard of care clot, tissue and arterial blood during standard of care cerebrovascular procedure for lab analysis.
Study: NCT04086238

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Capsules containing a combination of decitabine and THU
Study: NCT02108899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval practice effect using descriptive stories and free-call tests without feedback
Description: In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval practice effect using descriptive stories and free-call tests without feedback
Description: In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts.
Study: NCT01459835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: media diet
Description: advice and tips and tools for healthy non violent TV viewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional intervention
Description: advice on healthy eating
Study: NCT02611765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin G intramuscular 7.2 million units
Description: Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzathine penicillin G intramuscular 2.4 million units
Description: A single dose of intramuscular 2.4 million units of benzathine penicillin G
Study: NCT02874833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.
Study: NCT02105519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine (AdimFlu-S)
Description: Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine (AdimFlu-S)
Description: Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.
Study: NCT00635986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100 mcg Fentanyl intravenous or epidural route
Study: NCT01134263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
Description: 0.5 ml, Subcutaneous (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
Description: 0.5 ml, SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
Description: 0.5 ml, SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
Description: 0.5 ml, Subcutaneous (SC)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl 0.9%
Description: 0.5 ml, SC
Study: NCT03148067

Intervention type: PROCEDURE
Intervention: Intramedullary nailing for fracture fixation
Study: NCT04413942

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FB825
Description: Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation buffer
Study: NCT02591030

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GEMCIS
Description: At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~* Cisplatin 25 mg/m² over 1 hour at D1 and D8~* Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfirinox
Description: At D1 of each cycle, i.e. every 15 days for 6 months:~* Oxiplatin: 85 mg/m² (IP/120 minutes)~* Irinotecan: 180 mg/m² (IV/90 minutes)~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine \[calcium levofolinate\]) (IV/2 hours), via a Y connector at the same time as irinotecan~* 5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1